Abstract
PURPOSE OF REVIEW: There is conflicting data on the effectiveness of the currently recommended endoscopic surveillance strategy in non-dysplastic BE patients. We reviewed the literature to evaluate the (cost) effectiveness of the current surveillance strategy. We also reviewed critical strategies and new technologies which could improve dysplasia detection. RECENT FINDINGS: Adherence to the current EGD surveillance guidelines is suboptimal with high rates of missed dysplasia/EAC. The influence of surveillance on EAC mortality appears modest. Careful cleansing, inspection and sampling of the BE mucosa using high resolution while light and (electronic) chromoendoscopy is critical. Newer sampling techniques coupled with computer aided diagnosis and emerging imaging technologies have shown promise in improving dysplasia detection. Personalized surveillance with risk stratification based on risk factors for progression may be on the horizon. SUMMARY: Current BE surveillance strategy will likely be further refined and optimized by emerging new technologies in tissue sampling, advanced imaging and risk stratification.
Cite
CITATION STYLE
Gibbens, Y., & Iyer, P. G. (2020). What Is the Optimal Surveillance Strategy for Non-dysplastic Barrett’s Esophagus? Current Treatment Options in Gastroenterology, 18(3), 369–383. https://doi.org/10.1007/s11938-020-00297-9
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.